Results 71 to 80 of about 444,347 (295)

Present and Future in the Treatment of Diabetic Kidney Disease

open access: yesJournal of Diabetes Research, 2015
Diabetic kidney disease is the leading cause of end-stage renal disease. Albuminuria is recognized as the most important prognostic factor for chronic kidney disease progression.
Borja Quiroga   +2 more
doaj   +1 more source

Mitral Transcatheter Edge‐to‐Edge Repair in Patients With Advanced Heart Failure: A Single‐Center Experience and Insights Into Anatomical and Clinical Determinants of Procedural Complexity

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Advanced heart failure (HF) remains a clinical challenge, and mitral transcatheter edge‐to‐edge repair (M‐TEER) has emerged as a potential bridging strategy. Aims To describe the clinical outcomes of M‐TEER in a single‐center cohort of patients with advanced HF and to identify anatomical and clinical features potentially associated ...
Pedro Castilhos de Freitas Crivelaro   +8 more
wiley   +1 more source

Angiotensin II Receptor Antagonists and Hypertension

open access: yesClinical and Experimental Hypertension, 1999
Over recent years, a number of imidazole derivatives that specifically bind to the angiotensin II type 1 receptor, thereafter called sartans, have been developed and made available to the clinician. Whether targeting antihypertensive treatment with such a high specificity within the renin cascade may carry major clinical advantage over inhibiting ...
A, Mimran, J, Ribstein, G, DuCailar
openaire   +2 more sources

Cardiovascular‐Kidney‐Metabolic Syndrome in People With HIV: An Emerging Frontier for Clinical Pharmacology

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
As antiretroviral therapy (ART) prolongs lifespans, people with HIV (PWH) face a new syndemic: Cardiovascular‐Kidney‐Metabolic (CKM) syndrome. Yet CKM in PWH is poorly characterized. Inflammation, complex pharmacokinetic (PK) alterations, ART‐associated metabolic effects, and gut dysbiosis amplify risk. Managing CKM increases medication burden, thereby
Aaron S. Devanathan, Thomas D. Nolin
wiley   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon   +10 more
wiley   +1 more source

How should anti-hypertensive medications be adjusted before screening for primary aldosteronism?

open access: yesJournal of the Formosan Medical Association
Anti-hypertensive medications may affect plasma renin activity and/or plasma aldosterone concentration, misleading the interpretation of the aldosterone-to-renin ratio when screening for primary aldosteronism. The Task Force of Taiwan PA recommends that,
Jin-Ying Lu   +15 more
doaj   +1 more source

Cardiorenal Syndrome: Diagnosis and Treatment

open access: yesPočki, 2017
In the diagnosis of cardiorenal syndrome (CRS), the biological markers are widely used, they can be applied to identify the pathophysiological stages of CRS, to assess the amount of risk, prognosis and outcome, as well as to monitor the effectiveness of ...
O.O. Melnyk
doaj   +1 more source

Implementation of OMOP and ConcePTION Common Data Models in CPRD GOLD: Risk of Bleeding and Cardiovascular Outcomes From Anticoagulant Use

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The impact of the choice of common data model (CDM) approach on the study results in a real‐world evidence (RWE) study is unknown. We aimed to determine potential differences in the results of an RWE study when data were mapped to two different CDMs, ConcePTION and OMOP. With the same instance of CPRD GOLD, data were mapped to both CDMs. Using the same
Nicholas B. Hunt   +8 more
wiley   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri   +10 more
wiley   +1 more source

A role for the brain RAS in Alzheimer's and Parkinson's diseases

open access: yesFrontiers in Endocrinology, 2013
The brain renin-angiotensin system (RAS) has available the necessary functional components to produce the active ligands angiotensins II, III, IV, angiotensin (1-7), and angiotensin (3-7).
John William Wright   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy